Becker's Hospital Review - Cardiology

SEPTEMBER 27, 2023

General Hospital has the lowest 30-day readmission rate for heart failure in the country, according to CMS data. Lancaster (Pa.)

Heart Failure 52

Heart Failure Hospital CMS 52

Circulation

NOVEMBER 11, 2024

Background:Assessing clinical complexity in heart failure (HF) patients is essential for effective resource allocation. Despite notable limitations, CMS currently uses administrative claims to estimate complexity and determine provider payments. Circulation, Volume 150, Issue Suppl_1 , Page A4147247-A4147247, November 12, 2024.

CMS 40

CMS Heart Failure Hospital Risk Factors 40

DAIC

MAY 2, 2024

About the CardiAMP Cell Therapy Program Designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.

Ischemia 95

Ischemia Angina Heart Failure Outcomes 95

CardiacWire

DECEMBER 10, 2023

A new study in European Heart Journal – Digital Health showed that Us2.ai’s ai’s AI echo algorithm can interpret echocardiographic strain images with similar accuracy as conventional measurements, highlighting how AI can democratize cardiac strain exams and improve heart failure assessments. in Taiwanese cohort; −15.4

Heart Failure 59

Heart Failure Reimbursement CMS Outpatient 59

American College of Cardiology

FEBRUARY 1, 2025

Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. BMC Med2015;13(74). Page RL 2nd, O'Bryant CL, Cheng D, et al. Circulation.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

JULY 25, 2024

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

Becker's Hospital Review - Cardiology

SEPTEMBER 3, 2024

have the lowest death rate for heart failure patients in the country, according to CMS data. Chicago-based Northwestern Memorial Hospital and VA Boston Healthcare System-Jamaica Plain (Mass.)

Heart Failure 124

Heart Failure Hospital CMS 124

DAIC

MARCH 7, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

DECEMBER 8, 2023

The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. I am excited to be able to include the advanced heart failure patients in the trial," commented Dr. Grafton.

Technology 113

Technology Heart Failure Heart Transplant Transplant 113

DAIC

JULY 29, 2024

Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR. Building on an investment made in 2016, Edwards has exercised its option to acquire Endotronix , a leader in heart failure (HF) management solutions.

Innovation 105

Innovation Aortic valve Aortic CMS 105

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient 1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient ConclusionPatient discharge disposition and comorbidities are driving factors in 90‐day readmissions following an ischemic stroke and differ from 30‐day readmissions.

Risk Factors 40

Risk Factors Stroke Strokes Medicare 40